ClinicalTrials.gg
CompletedNCT03945773CaboPointUpdated Oct 6, 2026Results posted

Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

A Phase 2 interventional study of Cabozantinib in Locally Advanced or Metastatic Renal Cell Carcinoma, sponsored by Ipsen. Completed at 40 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Ipsen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing cabozantinib in Carcinoma, Renal Cell — 11 open to participants now, 23 under way, 4 of them phase 3. cabozantinib · Carcinoma, Renal Cell.

Enrollment
13th of 42
127 · median 44
Started
2020
with 4 others
Phase 2
25 of 42
6 open now
Registered
20th of 42
by date

Among the 42 studies testing cabozantinib in Carcinoma, Renal Cell, this one is the 13th largest by enrollment, is one of 5 that started in 2020, is one of 25 in phase 2, and was the 20th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

11 of the 42 studies testing cabozantinib in Carcinoma, Renal Cell are open now, in 6 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing cabozantinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.

03

Conditions studied

  • Locally Advanced or Metastatic Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects must fulfil all the following criteria to be included in the study:

  1. Subjects must provide a signed prior to any study-related procedures;
  2. Male or female subjects must be aged ≥18 years on the day the informed consent is signed;
  3. Subjects must have confirmed unresectable, locally advanced (defined as disease not eligible for curative surgery or radiation therapy) or RCC with a clear-cell carcinoma component;
  4. Subjects must have radiographic disease progression, according to Investigator's judgement following treatment with CPI (ipilimumab plus nivolumab) (Cohort A) or CPI in combination with VEGF-targeted therapy (Cohort B);
  5. Subjects present ≥1 target lesion according to 1.1 per Investigator;
  6. Subjects should have (ECOG) status 0-1;
  7. Subjects with treated are eligible if metastases have been shown to be stable as per Investigator's judgement;
  8. Subjects must have adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 15 days before baseline:

    1. (ANC) ≥ 1500/mm3 (≥ 1.5 GI/L).
    2. ≥ 100,000/mm3 (≥ 100 GI/L).
    3. ≥ 9 g/dL (≥ 90 g/L).
    4. (ALT) and aspartate aminotransferase (AST) \< 3.0 × (ULN).
    5. Total ≤ 1.5 × ULN. For subjects with Gilbert's disease ≤ 3 mg/dL (≤ 51.3 μmol/L).
    6. Serum creatinine ≤ 2.0 × ULN or calculated ≥ 30 mL/min (≥ 0.5 mL/sec) using the Cockcroft-Gault equation
    7. Urine protein-to-creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol) creatinine or 24-hour urine protein \< 1 g.
  9. Subject must have recovered to baseline or ≤ Grade 1 per v5 from toxicities related to any prior treatments, unless Adverse Events (AE(s)) are clinically nonsignificant and/or stable on supportive therapy as determined by the Investigator;
  10. Subject must have completed a taper if he/she had an immune-related adverse event associated with immune CPI;
  11. Female subjects of (i.e. less than or equal to 2 years and not surgically sterile) must provide a negative pregnancy test within 7 days prior to the start of study treatment. If a urine test cannot be confirmed as negative, a negative serum pregnancy test is required;
  12. Female subjects of childbearing potential (i.e. less than or equal to 2 years post-menopause and not surgically sterile) and their partners must agree to use highly effective methods of that alone or in combination result in a failure rate of less than 1% per year when used consistently and correctly during the course of the study and for 4 months after the last dose of study treatment;
  13. All male participants must agree to refrain from donating sperm and unprotected sexual intercourse with female partners during the study and for 120 days after the last dose of study treatment;
  14. Subjects must be willing and able to comply with study requirements, remain at the site for the required duration of each study visit and be willing to return to the investigational site for the follow up evaluation, as specified in the protocol
  15. Subjects must be covered by social security or be the beneficiary of such a system (only applicable for French subjects).

Exclusion criteria

Exclusion Criteria:

Subjects will not be included in the study if the subject:

  1. Inability to swallow tablets;
  2. Was treated with any other medicinal product (IMP) within the last 30 days before baseline;
  3. Was previously treated with cabozantinib;
  4. Has a to Magnetic Resonance Imaging (MRI) or contrast medium used for Contrast Tomography (CT)-scan;
  5. Presents untreated brain or , or current clinical or radiographic progression of known ;
  6. Has a diagnosis of a serious cardiovascular disorder:

    1. Congestive heart failure class 3 or 4, unstable angina pectoris, or serious cardiac arrhythmias;
    2. Uncontrolled hypertension, defined as sustained blood pressure (BP) (>140 mm Hg systolic or >90 mm Hg diastolic pressure) despite optimal antihypertensive treatment;
    3. Stroke (including (TIA)), myocardial infarction (MI) or other ischaemic event, or thromboembolic event (e.g. deep venous thrombosis, pulmonary embolism) within 6 months before screening;
    4. History of risk factors for torsades de pointes (e.g., long syndrome);
  7. Is receiving concomitant anticoagulation with coumarin agents (e.g. warfarin), direct thrombin inhibitor dabigatran, Direct Factor Xa inhibitors betrixaban or inhibitors (e.g. clopidogrel); Note: The following are allowed anticoagulants: prophylactic use of low-dose aspirin for cardioprotection (per local applicable guidelines) and low dose, low molecular weight heparin (LMWH) are permitted. Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in patients without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before baseline without hemorrhagic complications from the anticoagulation regimen or the tumour.
  8. Has a gastrointestinal (GI) disorder including those associated with a high risk of perforation or fistula formation:

    (a) Tumours invading the GI tract, active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic or biliary duct, or gastric outlet obstruction; b) Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before screening; Note: Complete healing of an intra-abdominal abscess must have been confirmed before screening

  9. Presents a corrected QT (QTc) interval calculated by the Fridericia formula (QTcF) > 500 msec within 1 month prior to baseline; Note: If a single shows a QTcF with an absolute value > 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility
  10. Presents clinically significant haematuria, hematemesis, or haemoptysis of >0.5 teaspoon (2.5 mL) of red blood, or other history of significant bleeding (e.g.

    pulmonary haemorrhage) within 3 months before screening;

  11. Presents cavitating pulmonary lesion(s) or known endobronchial disease manifestation;
  12. Presents lesions invading major pulmonary blood vessels;
  13. Has been diagnosed with other clinically significant disorders such as:

    1. Serious nonhealing wound/ulcer/bone fracture;
    2. Malabsorption syndrome;
    3. Uncompensated/symptomatic hypothyroidism;
    4. Moderate to severe hepatic impairment ( B or C);
    5. Requirement for haemodialysis or peritoneal dialysis;
    6. History of solid organ transplantation;
  14. Has a predicted of less than 3 months;
  15. Has had prior surgery within 4 weeks prior to baseline. Note: If the subject has undergone major surgery, complete wound healing must have occurred 1 month prior to baseline
  16. Has had palliative radiation therapy for bone within 2 weeks or for radiation fields including viscera within 4 weeks prior to baseline. Note: Resolution/healing of side effects must be complete prior to baseline;
  17. Has a history of another active within 3 years from screening except for locally curable cancers that have been apparently cured, such as low-grade thyroid carcinoma, prostate cancer not requiring treatment (Gleason Grade ≤6), basal or squamous cell skin cancer, superficial bladder cancer, in situ melanoma, in situ prostate, cervix or breast carcinoma or other treated malignancies with \<5% chance of relapse according to the Investigator;
  18. Has a history of allergy to study treatment components or agents with a similar chemical structure or any used in the formulation as listed in the Summary of Product Characteristics (SmPC) document;
  19. Has rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption are also excluded;
  20. Has a serious medical or psychiatric condition that renders the subject unable to understand the nature, scope and possible consequences of the study, and/or presents an uncooperative attitude;
  21. Is pregnant or breastfeeding. A β-human chorionic gonadotrophin (HCG) serum pregnancy test will be performed up to 7 days prior to baseline for all female subjects of (i.e. less than or equal to 2 years and not surgically sterile);
  22. Is likely to require treatment during the study with drugs that are not permitted by the study protocol;
  23. Has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the subject's safety
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Cohort A

    Subjects who radiographically progressed after one prior line by CPI therapy with ipilimumab and nivolumab.

    Drug: Cabozantinib

  • Experimental
    Cohort B

    Subjects who radiographically progressed after one prior line by CPI therapy combined with VEGF-targeted therapy.

    Drug: Cabozantinib

Interventions

  • Oral tablets of 60mg, 40mg and 20 mg.

    Also known as: Cabometyx

06

What researchers measure

Primary outcomes

  1. Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review

    ORR was defined as the percentage of participants who achieved a partial response (PR) or complete response (CR) at any timepoint as determined by independent central review per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. The confidence interval of the ORR was calculated using Clopper-Pearson exact method.

    Time frame: Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months

Secondary outcomes

  1. Time to Response (TTR) Assessed by Independent Central Review and Investigator

    TTR was defined as the time from start of study treatment to the date of first evidence of response (PR or CR as determined by independent central review and Investigator per RECIST 1.1). The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.

    Time frame: Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months

  2. Duration of Response (DOR) Assessed by Independent Central Review and Investigator

    DOR was defined as the time from first documented response (PR or CR as determined by independent central review and Investigator per RECIST 1.1) to either disease progression (as determined by independent central review and Investigator per RECIST 1.1) or death due to any cause, whichever occurs first. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. The progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of ≥ 5 millimeters (mm). DOR was calculated using the Kaplan-Meier method.

    Time frame: Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months

  3. Disease Control Rate (DCR) Assessed by Independent Central Review and Investigator

    DCR was defined as the percentage of participants who achieved a PR, CR or stable disease (SD) as determined by independent central review and Investigator per RECIST 1.1. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. The SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. The PD was defined at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of ≥ 5 mm.

    Time frame: Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months

  4. Progression-free Survival (PFS) Assessed by Independent Central Review and Investigator

    PFS was defined as the time from start of study treatment to either disease progression (as determined by independent central review and Investigator per RECIST 1.1) or death due to any cause, whichever occurs first. The PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of ≥ 5 mm. PFS was calculated using the Kaplan-Meier method.

    Time frame: Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months

  5. Cohort B: Objective Response Rate Assessed by Independent Central Review

    ORR was defined as the percentage of participants who achieved a PR or CR at any timepoint as determined by independent central review per RECIST 1.1. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. The CI of the ORR was calculated using Clopper-Pearson exact method.

    Time frame: Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months

  6. Objective Response Rate Assessed by Investigator

    ORR was defined as the percentage of participants who achieved a PR or CR at any timepoint as determined by Investigator per RECIST 1.1. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. The CI of the ORR was calculated using Clopper-Pearson exact method.

    Time frame: Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months

  7. Overall Survival (OS) Assessed by Investigator

    OS was defined as the time from the start of treatment until death due to any cause. OS was calculated using the Kaplan-Meier method.

    Time frame: From the start of study treatment (Day 1) up to end of study, 45 months

  8. Change From Baseline in Functional Assessment of Cancer Therapy-Kidney Cancer Symptom Index (FKSI-DRS) Score at Month 40

    The FKSI-DRS questionnaire consisted of 9-items to evaluate participant's symptoms in the past 7 days such as lack of energy, pain, weight-loss, bone-pain, shortness of breath, fatigue, fever, blood in urine etc. Participants rated each question from 0 (not at all) to 4 (very much). Total score was calculated as the sum of the item responses divided by the number of items completed and multiplied by the total number of items in the scale. Total score ranged from 0 to 36. Higher scores indicated less symptoms. Baseline was defined as the last questionnaire answered prior to the first dose of study drug. A negative change from baseline indicated worse outcome.

    Time frame: Baseline (Day 1) and Month 40

07

Results

Posted Dec 19, 2024

Participant flow

This Phase II, open-label study was conducted in participants with unresectable, locally advanced or metastatic renal cell carcinoma with a clear-cell component who progressed after 1st line treatment with checkpoint inhibitors (CPI) at 40 sites in 7 countries (Austria, France, Germany, Netherlands, Spain, Switzerland, and the United Kingdom) between 08 January 2020 and 12 February 2026. A total of 127 participants were enrolled in the study.

Participant flow — Overall Study
MilestoneCohort ACohort B
Started8542
Participants who entered treatment extension43
Completed3519
Not completed5023
Withdrew: Consent withdrawn11
Withdrew: Lost to follow-up10
Withdrew: Death4622
Withdrew: Physician decision10
Withdrew: Other10

Outcome measures

PrimaryCohort A: Objective Response Rate (ORR) Assessed by Independent Central Review

ORR was defined as the percentage of participants who achieved a partial response (PR) or complete response (CR) at any timepoint as determined by independent central review per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. The confidence interval of the ORR was calculated using Clopper-Pearson exact method.

Time frame:
Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months
Reported as:
Number · percentage of participants
Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review
percentage of participantsCohort A
Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review40.5 (29.6 to 52.1)
SecondaryTime to Response (TTR) Assessed by Independent Central Review and Investigator

TTR was defined as the time from start of study treatment to the date of first evidence of response (PR or CR as determined by independent central review and Investigator per RECIST 1.1). The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.

Time frame:
Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months
Reported as:
Median · months
Time to Response (TTR) Assessed by Independent Central Review and Investigator
monthsCohort ACohort B
Independent Central Review Assessment2.8 (2.4 to 13.8)2.8 (2.7 to 8.3)
Investigator Assessment2.8 (1.8 to 19.1)2.8 (2.5 to 22.1)
SecondaryDuration of Response (DOR) Assessed by Independent Central Review and Investigator

DOR was defined as the time from first documented response (PR or CR as determined by independent central review and Investigator per RECIST 1.1) to either disease progression (as determined by independent central review and Investigator per RECIST 1.1) or death due to any cause, whichever occurs first. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. The progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of ≥ 5 millimeters (mm). DOR was calculated using the Kaplan-Meier method.

Time frame:
Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months
Reported as:
Median · months
Duration of Response (DOR) Assessed by Independent Central Review and Investigator
monthsCohort ACohort B
Independent Central Review AssessmentNA (11.6 to NA)8.3 (5.6 to NA)
Investigator Assessment11.2 (8.3 to 16.7)8.3 (3.7 to 11.1)
SecondaryDisease Control Rate (DCR) Assessed by Independent Central Review and Investigator

DCR was defined as the percentage of participants who achieved a PR, CR or stable disease (SD) as determined by independent central review and Investigator per RECIST 1.1. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. The SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. The PD was defined at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of ≥ 5 mm.

Time frame:
Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) Assessed by Independent Central Review and Investigator
percentage of participantsCohort ACohort B
Independent Central Review Assessment84.8 (75.0 to 91.9)82.5 (67.2 to 92.7)
Investigator Assessment83.5 (73.9 to 90.7)81.0 (65.9 to 91.4)
SecondaryProgression-free Survival (PFS) Assessed by Independent Central Review and Investigator

PFS was defined as the time from start of study treatment to either disease progression (as determined by independent central review and Investigator per RECIST 1.1) or death due to any cause, whichever occurs first. The PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of ≥ 5 mm. PFS was calculated using the Kaplan-Meier method.

Time frame:
Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months
Reported as:
Median · months
Progression-free Survival (PFS) Assessed by Independent Central Review and Investigator
monthsCohort ACohort B
Independent Central Review Assessment10.9 (8.2 to 14.2)8.3 (5.6 to 11.1)
Investigator Assessment10.9 (8.2 to 13.6)8.2 (5.6 to 9.2)
SecondaryCohort B: Objective Response Rate Assessed by Independent Central Review

ORR was defined as the percentage of participants who achieved a PR or CR at any timepoint as determined by independent central review per RECIST 1.1. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. The CI of the ORR was calculated using Clopper-Pearson exact method.

Time frame:
Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months
Reported as:
Number · percentage of participants
Cohort B: Objective Response Rate Assessed by Independent Central Review
percentage of participantsCohort B
Cohort B: Objective Response Rate Assessed by Independent Central Review27.5 (14.6 to 43.9)
SecondaryObjective Response Rate Assessed by Investigator

ORR was defined as the percentage of participants who achieved a PR or CR at any timepoint as determined by Investigator per RECIST 1.1. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. The CI of the ORR was calculated using Clopper-Pearson exact method.

Time frame:
Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months
Reported as:
Number · percentage of participants
Objective Response Rate Assessed by Investigator
percentage of participantsCohort ACohort B
Objective Response Rate Assessed by Investigator49.4 (38.4 to 60.5)33.3 (19.6 to 49.5)
SecondaryOverall Survival (OS) Assessed by Investigator

OS was defined as the time from the start of treatment until death due to any cause. OS was calculated using the Kaplan-Meier method.

Time frame:
From the start of study treatment (Day 1) up to end of study, 45 months
Reported as:
Median · months
Overall Survival (OS) Assessed by Investigator
monthsCohort ACohort B
Overall Survival (OS) Assessed by Investigator24.3 (18.5 to 31.8)24.1 (17.1 to NA)
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Kidney Cancer Symptom Index (FKSI-DRS) Score at Month 40

The FKSI-DRS questionnaire consisted of 9-items to evaluate participant's symptoms in the past 7 days such as lack of energy, pain, weight-loss, bone-pain, shortness of breath, fatigue, fever, blood in urine etc. Participants rated each question from 0 (not at all) to 4 (very much). Total score was calculated as the sum of the item responses divided by the number of items completed and multiplied by the total number of items in the scale. Total score ranged from 0 to 36. Higher scores indicated less symptoms. Baseline was defined as the last questionnaire answered prior to the first dose of study drug. A negative change from baseline indicated worse outcome.

Time frame:
Baseline (Day 1) and Month 40
Reported as:
Mean · score on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Kidney Cancer Symptom Index (FKSI-DRS) Score at Month 40
score on a scaleCohort ACohort B
Change From Baseline in Functional Assessment of Cancer Therapy-Kidney Cancer Symptom Index (FKSI-DRS) Score at Month 40-3.0 ± 5.4-2.4 ± 5.6

Adverse events

Collected over Adverse events and all-cause mortality (deaths) were collected from first dose of study treatment (Day 1) up to end of follow up per participant, approximately 73 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A46/85 (54.1%)51/85 (60%)85/85 (100%)
Cohort B22/42 (52.4%)16/42 (38.1%)41/42 (97.6%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventCohort ACohort B
COVID-19Infections and infestations8/855/42
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/853/42
DiarrhoeaGastrointestinal disorders2/852/42
PneumoniaInfections and infestations3/851/42
SepsisInfections and infestations3/850/42
Febrile neutropeniaBlood and lymphatic system disorders0/851/42
Inguinal herniaGastrointestinal disorders1/851/42
VomitingGastrointestinal disorders1/851/42
Abdominal pain upperGastrointestinal disorders0/851/42
NauseaGastrointestinal disorders0/851/42
Most frequent other events
Showing 10 of 73
Most frequent other events
EventCohort ACohort B
DiarrhoeaGastrointestinal disorders60/8531/42
Decreased appetiteMetabolism and nutrition disorders41/8524/42
HypertensionVascular disorders43/8520/42
StomatitisGastrointestinal disorders33/8520/42
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders39/8510/42
FatigueGeneral disorders32/8519/42
HypothyroidismEndocrine disorders25/8514/42
Aspartate aminotransferase increasedInvestigations18/8514/42
NauseaGastrointestinal disorders27/8513/42
Alanine aminotransferase increasedInvestigations19/8513/42

Baseline characteristics

Safety population included all included participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)Cohort ACohort BTotal
Mean63.2 ± 9.066.2 ± 9.764.2 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Cohort ACohort BTotal
Female22931
Male633396
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort ACohort BTotal
White503585
Missing35742
08

Study locations

40 sites
  • SALK - Salzburger Landesklinik
    Salzburg, A-5020, Austria
  • CHRU Besançon
    Besançon, 25000, France
  • Centre Jean Perrin
    Clermont-Ferrand, 63011, France
  • Centre Léon Bérard
    Lyon, 69008, France
  • Institut Paoli Calmettes
    Marseille, 13009, France
  • Institut de Cancérologie de Lorraine
    Nancy, 54511, France
  • CHU de Nîmes - Institut de Cancérologie du Gard
    Nîmes, 30029, France
  • Institut Mutualiste Montsouris
    Paris, 75014, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
  • Institut de Cancérologie de l'Ouest
    Saint-Herblain, 44800, France
  • CHU Strasbourg
    Strasbourg, 67091, France
  • Institut Claudius Régaud
    Toulouse, 31059, France
  • Gustave Roussy
    Villejuif, 94805, France
  • Universitätsmedzin Charité
    Berlin, D-10117, Germany
  • University Hospital Carl Gustav Carus Dresden
    Dresden, D-1307, Germany
  • Universitätsklinikum Essen
    Essen, D-45147, Germany
  • University Cancer Center Hamburg Eppendorf
    Hamburg, d-20246, Germany
  • Medizinische Hochschule Hannover
    Hanover, D-30625, Germany
  • Klinikum Der Friedrich-Schiller-Universitaet Jena
    Jena, D-07747, Germany
  • Universitätsklinikum Schleswig-Holstein
    Lübeck, D-23538, Germany
  • Otto-von-Guericke-Universität University hospital Magdeburg
    Magdeburg, D-39120, Germany
  • University, Hospital Münster
    Münster, D-48149, Germany
  • Caritas Krankenhaus St.Josef Klinik für Urologie
    Regensburg, D-93053, Germany
  • University Hospital Tuebingen
    Tübingen, D-72076, Germany
  • The Netherlands Cancer Institute - Oncology
    Amsterdam, 1066 CX, Netherlands
  • Maxima Medisch Centrum
    Eindhoven, 5604 DB, Netherlands
  • Leiden University Medical Center
    Leiden, 2300-RC, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • Hospital de La Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital Lucus Augusti
    Lugo, 27003, Spain
  • M.D. Anderson Center Madrid
    Madrid, 28033, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Universitätsspital Bern, Inselspital
    Bern, 3010, Switzerland
  • Centre Hospitalier Universitaire Vaudois
    Lausanne, 1011, Switzerland
  • Kantonsspital St. Gallen
    Sankt Gallen, 9007, Switzerland
  • Western General Hospital - Edinburgh Cancer Centre
    Edinburgh, EH4 2XU, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, G12 0YN, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
  • Mount Vernon Hospital
    Northwood, HA6 2RN, United Kingdom
  • Royal Cornwall Hospital (RCH) - Sunrise Centre
    Truro, TR1 3LJ, United Kingdom
09

References and documents

Publications

  • Albiges L, Schmidinger M, Taguieva-Pioger N, Perol D, Grunwald V, Guemas E. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. Future Oncol. 2022 Mar;18(8):915-926. doi: 10.2217/fon-2021-1006. Epub 2021 Dec 16. PubMed 34911359 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in May 2023, 40 months.

Results were first posted in Dec 2024, 1 year 7 months after primary completion.

Of 47 industry-sponsored phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 40 months is above that.

Counting every sponsor, half of 231 studies reached it within 59 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2019
First posted
May 10, 2019
StartActual
Jan 8, 2020
Primary completionActual
May 11, 2023
CompletionActual
Feb 12, 2026
Results first posted
Dec 19, 2024
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and design details
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03945773
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
May 10, 2019
Start date
Jan 8, 2020
Primary completion
May 11, 2023
Completion
Feb 12, 2026
Results posted
Dec 19, 2024
Last update
Oct 6, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion